世界卫生组织肿瘤分类与免疫组化及分子病理的外部质量保证
本文基于2021年Princeton整合病理研讨会的报告,阐述WHO肿瘤分类(第5版乳腺肿瘤)如何与乳腺病理的质量保证要求相衔接,涵盖免疫组化和分子病理。WHO分类提供肿瘤诊断的国际标准,病理技术需内部和外部质量保证以确保报告准确。
要点
- WHO肿瘤分类第5版乳腺肿瘤是乳腺病理诊断的国际标准。
- 免疫组化和分子病理技术需内部和外部质量保证。
- 质量保证确保患者管理所需的准确病理报告。
核心结论
- WHO肿瘤分类提供基于临床和研究证据的肿瘤诊断国际标准。
- 病理技术需内部和外部质量保证以确保准确报告。
研究设计与样本
- 基于2021年4月11日第八届Princeton整合病理研讨会乳腺病理专场报告。
- 数据来源为WHO肿瘤分类第5版乳腺肿瘤条目及国际病理质量网络发布的指南。
临床怎么用
- 乳腺病理诊断应参照WHO肿瘤分类第5版乳腺肿瘤条目。
- 免疫组化和分子病理检测应实施内部和外部质量保证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT.—: This article is based on a talk given by the lead author at the Eigth Annual Princeton Integrated Pathology Symposium: Breast Pathology, on Sunday, April 11, 2021. OBJECTIVE.—: To show how the World Health Organization (WHO) Classification of Tumours links to the requirements for quality assurance in breast pathology, including both immunohistochemistry and molecular pathology. DATA SOURCES.—: The WHO Classification of Tumours 5th edition Breast Tumours entries formed the basis of the talk, together with guidance published by the International Quality Network for Pathology. CONCLUSIONS.—: The WHO Classification of Tumours provides a definitive set of international standards for tumor diagnosis contributed by experts, based on available clinical and research evidence. Techniques used in pathology need internal and external quality assurance to ensure accurate reports for patient management.
引用
- Cree IA, Lokuhetty D, Tan PH, et al. The World Health Organization Classification of Tumors and External Quality Assurance for Immunohistochemistry and Molecular Pathology. Arch Pathol Lab Med. 2022. PMID: 35671156. doi:10.5858/arpa.2021-0491-RA
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。